1Ling Z, Eric P, Jeffrey L, et al. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes[J]. Leukemia Research, 2015, 39(1): 6-17.
2Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5- methylcytosine to 5-hydroxymethylcytosine in mammali- an DNA by MLL partner TETI[J]. Science, 2009, 324 (5959): 930-935.
4Losman JA, Kaelin Jr WG. What a difference a hydrox- yl makes: mutant IDH,(R)-2-hydroxyglutarate, and can- cer[J]. Genes Dev, 2013, 27(8): 836-852.
5Graubert T, Walter MJ. Genetics of myelodysplastic syn- dromes: new insights[G]. Hematology Am Soc Hematol Educ Program, 2011: 543-549.
6Song WJ, Sullivan MG, Legare RD, et al. Haploinsuffi- eiency of CBFA2 causes familial thrombocytopenia with propen-sity to develop acute myelogenous leukaemia[J]. Nat Genet, 1999, 23(2): 166-175.
7Corces-Zimmerman MR, Majeti R. Pre-leukemic evolu- tion of hematopoietic stem cells: the importance of early mutations in leukemogenesis[J]. Leukemia, 2014, 28 (12): 2276-2282.
8Chu SH, Heiser D, Li L, et al. FLT3-ITD knockin im- pairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm[J]. Cell Stem Cell, 2012, 11(3): 346-358.
9Schmidt M, Rinke J, Sch~ifer V, et al. Molecular-defined clonal evolution in patients with chronic myeloid leuke- mia independent of the BCR-ABL status[J]. Leukemia, 2014, 28(12): 2292-2299.
